Virtual Care Isn’t What It Used to Be – It’s Getting BetterBy Derek Streat
Derek Streat is CEO of DexCare.
Virtual emerged as a vital access bridge during the pandemic, ensuring that patients…
Continue Reading
Shelli Pavone, CEO & President, Inlightened
Last month was Cancer Research Awareness Month, which is a great time to celebrate recent findings that the number of adults enrolled in oncology clinical trials has increased –…
Continue Reading
Ram Krishnan, CEO of Valant
Treatment plans are an often-overlooked element of quality mental health treatment. Some providers see them as inefficient busywork, a necessary evil to meet compliance standards. However, treatment plans in counseling…
Continue Reading
The MedCity Moves Podcast is back with another episode. During the episode, Senior Reporter Katie Adams discussed some of the executive hires and exits occurring in the healthcare world over the past month, including…
Continue Reading
Bambu AI augments psychological and behavioral treatments in two ways: by providing ongoing support between the patient’s weekly or monthly visits, and by summarizing the conversations that patients have with their Willow app and presenting…
Continue Reading
Bambu AI augments psychological and behavioral treatments in two ways: by providing ongoing support between the patient's weekly or monthly visits, and by summarizing the conversations that patients have with their Willow app and presenting…
Continue Reading
Florence Luna, Co-Founder and CEO of Fig Medical
The prior authorization process, integral for confirming the necessity and insurance coverage of medical treatments, has historically been an obstacle in healthcare. In its current state, it…
Continue Reading
Adam McMullin, MBA is CEO of AvaSure.
Tell me about yourself and the company.
I have led AvaSure for the past two years. I have had the privilege of being involved with a…
Some clinicians and healthcare professionals are ready and willing to welcome artificial intelligence to their daily routines. Others, though, are a bit more hesitant.”We’re all becoming less trustworthy of AI outcomes as we use…
Continue Reading
There is still a lot we don’t know when it comes to GLP-1s. How do these drugs’ side effects vary across different patients? How effective are these medications in the long term? Are barriers…
Continue Reading
